Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 11, 2013 - Issue 7
Submit an article Journal homepage
849
Views
8
CrossRef citations to date
0
Altmetric
Review

The challenge of managing pulmonary arterial hypertension in adults with congenital heart disease

Robert M Radke Adult Congenital and Valvular Heart Disease Center, Dept. of Cardiology and Angiology, University Hospital Münster, Münster, Germany. [email protected]
,
Gerhard-Paul Diller Adult Congenital and Valvular Heart Disease Center, Dept. of Cardiology and Angiology, University Hospital Münster, Münster, Germany
&
Helmut Baumgartner Adult Congenital and Valvular Heart Disease Center, Dept. of Cardiology and Angiology, University Hospital Münster, Münster, Germany
Pages 919-931 | Published online: 10 Jan 2014

References

  • Simonneau G, Robbins IM, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 54(Suppl. 1), S43–S54 (2009).
  • Hoeper MM. Definition, classification, and epidemiology of pulmonary arterial hypertension. Semin. Respir. Crit. Care Med. 30(4), 369–375 (2009).
  • Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br. Med. J. 2(5099), 755–762 (1958).
  • Engelfriet PM, Duffels MG, Möller T et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart 93(6), 682–687 (2007).
  • Lowe BS, Therrien J, Ionescu-Ittu R, Pilote L, Martucci G, Marelli AJ. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J. Am. Coll. Cardiol. 58(5), 538–546 (2011).
  • Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70(4), 580–587 (1984).
  • Beghetti M, Galiè N. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 53(9), 733–740 (2009).
  • Duffels MG, Engelfriet PM, Berger RM et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int. J. Cardiol. 120(2), 198–204 (2007).
  • McLaughlin VV, Presberg KW, Doyle RL et al.; American College of Chest Physicians. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126(Suppl. 1), 78S–92S (2004).
  • Humenberger M, Rosenhek R, Gabriel H et al. Benefit of atrial septal defect closure in adults: impact of age. Eur. Heart J. 32(5), 553–560 (2011).
  • Huang ZW, Fan ZX, Sun JT et al. The short- and medium-term results of transcatheter closure of atrial septal defect with severe pulmonary arterial hypertension. Heart Vessels 27(6), 603–609 (2012).
  • Therrien J, Rambihar S, Newman B et al. Eisenmenger syndrome and atrial septal defect: nature or nurture? Can. J. Cardiol. 22(13), 1133–1136 (2006).
  • Gatzoulis MA, Alonso-Gonzalez R, Beghetti M. Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease. Eur. Respir. Rev. 18(113), 154–161 (2009).
  • Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation 115(2), 163–172 (2007).
  • Schuuring MJ, Bouma BJ, Cordina R et al. Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease. Int. J. Cardiol. 164(1), 106–110 (2013).
  • Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 18(4 Pt 1), 533–547 (1958).
  • Rabinovitch M, Haworth SG, Castaneda AR, Nadas AS, Reid LM. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation 58(6), 1107–1122 (1978).
  • Farber HW, Loscalzo J. Pulmonary arterial hypertension. N. Engl. J. Med. 351(16), 1655–1665 (2004).
  • Haworth SG. Role of the endothelium in pulmonary arterial hypertension. Vascul. Pharmacol. 45(5), 317–325 (2006).
  • Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J. Clin. Invest. 122(12), 4306–4313 (2012).
  • Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113(13), 1708–1714 (2006).
  • Galiè N, Ghofrani HA, Torbicki A et al.; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 353(20), 2148–2157 (2005).
  • Schiffrin EL. Vascular endothelin in hypertension. Vascul. Pharmacol. 43(1), 19–29 (2005).
  • Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur. Respir. J. 31(2), 407–415 (2008).
  • Falcetti E, Hall SM, Phillips PG et al. Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 182(9), 1161–1170 (2010).
  • Diller GP, Dimopoulos K, Broberg CS et al. Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study. Eur. Heart J. 27(14), 1737–1742 (2006).
  • McLaughlin VV, Davis M, Cornwell W. Pulmonary arterial hypertension. Curr. Probl. Cardiol. 36(12), 461–517 (2011).
  • Benza RL, Miller DP, Gomberg-Maitland M et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 122(2), 164–172 (2010).
  • Mulder BJ. Changing demographics of pulmonary arterial hypertension in congenital heart disease. Eur. Respir. Rev. 19(118), 308–313 (2010).
  • Daliento L, Somerville J, Presbitero P et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur. Heart J. 19(12), 1845–1855 (1998).
  • Cantor WJ, Harrison DA, Moussadji JS et al. Determinants of survival and length of survival in adults with Eisenmenger syndrome. Am. J. Cardiol. 84(6), 677–681 (1999).
  • Saha A, Balakrishnan KG, Jaiswal PK et al. Prognosis for patients with Eisenmenger syndrome of various aetiology. Int. J. Cardiol. 45(3), 199–207 (1994).
  • Oya H, Nagaya N, Satoh T et al. Haemodynamic correlates and prognostic significance of serum uric acid in adult patients with Eisenmenger syndrome. Heart 84(1), 53–58 (2000).
  • Clarkson PM, Frye RL, DuShane JW, Burchell HB, Wood EH, Weidman WH. Prognosis for patients with ventricular septal defect and severe pulmonary vascular obstructive disease. Circulation 38(1), 129–135 (1968).
  • Moceri P, Dimopoulos K, Liodakis E et al. Echocardiographic predictors of outcome in Eisenmenger syndrome. Circulation 126(12), 1461–1468 (2012).
  • Diller GP, Alonso-Gonzalez R, Kempny A et al. B-type natriuretic peptide concentrations in contemporary Eisenmenger syndrome patients: predictive value and response to disease targeting therapy. Heart 98(9), 736–742 (2012).
  • Budts W, Van Pelt N, Gillyns H, Gewillig M, Van De Werf F, Janssens S. Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome. Heart 86(5), 553–558 (2001).
  • Post MC, Janssens S, Van de Werf F, Budts W. Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. Eur. Heart J. 25(18), 1651–1656 (2004).
  • Baumgartner H, Bonhoeffer P, De Groot NM et al.; Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC); Association for European Paediatric Cardiology (AEPC); ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur. Heart J. 31(23), 2915–2957 (2010).
  • Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation 115(8), 1039–1050 (2007).
  • Broberg CS, Bax BE, Okonko DO et al. Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease. J. Am. Coll. Cardiol. 48(2), 356–365 (2006).
  • Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J. Am. Coll. Cardiol. 28(3), 768–772 (1996).
  • Perloff JK, Rosove MH, Child JS, Wright GB. Adults with cyanotic congenital heart disease: hematologic management. Ann. Intern. Med. 109(5), 406–413 (1988).
  • Broberg CS, Ujita M, Prasad S et al. Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J. Am. Coll. Cardiol. 50(7), 634–642 (2007).
  • Ammash NM, Connolly HM, Abel MD, Warnes CA. Noncardiac surgery in Eisenmenger syndrome. J. Am. Coll. Cardiol. 33(1), 222–227 (1999).
  • Oechslin E. Eisenmenger’s syndrome. In: Adult Congenital Heart Disease. Gatzoulis M, Webb G, Daubeney P (Eds). Elsevier, PA, USA, 363–378 (2003).
  • Rubin LJ, Mendoza J, Hood M et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann. Intern. Med. 112(7), 485–491 (1990).
  • Fernandes SM, Newburger JW, Lang P et al. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am. J. Cardiol. 91(5), 632–635 (2003).
  • Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 99(14), 1858–1865 (1999).
  • Simonneau G, Barst RJ, Galie N et al.; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a doubleblind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 165(6), 800–804 (2002).
  • Olschewski H, Simonneau G, Galiè N et al.; Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 347(5), 322–329 (2002).
  • Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin LJ. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 48(7), 1433–1437 (2006).
  • Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC), European Respiratory Society (ERS), International Society of Heart and Lung Transplantation (ISHLT) et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 34(6), 1219–1263 (2009).
  • Galiè N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur. Heart J. 31(17), 2080–2086 (2010).
  • Galiè N, Beghetti M, Gatzoulis MA et al.; Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114(1), 48–54 (2006).
  • Gatzoulis MA, Beghetti M, Galiè N et al.; BREATHE-5 Investigators. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int. J. Cardiol. 127(1), 27–32 (2008).
  • Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease. Heart 91(11), 1447–1452 (2005).
  • van Loon RL, Hoendermis ES, Duffels MG et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am. Heart J. 154(4), 776–782 (2007).
  • Vis JC, Duffels MG, Mulder P et al. Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease. Int. J. Cardiol. 164(1), 64–69 (2013).
  • Diller GP, Alonso-Gonzalez R, Dimopoulos K et al. Disease targeting therapies in patients with Eisenmenger syndrome: response to treatment and long-term efficiency. Int. J. Cardiol. doi:10.1016/j.ijcard.2012.02.007 (2012) (Epub ahead of print).
  • Tay EL, Papaphylactou M, Diller GP et al. Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy. Int. J. Cardiol. 149(3), 372–376 (2011).
  • Schulze-Neick I, Gilbert N, Ewert R et al. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy. Am. Heart J. 150(4), 716 (2005).
  • Zhang ZN, Jiang X, Zhang R et al. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Heart 97(22), 1876–1881 (2011).
  • Mukhopadhyay S, Sharma M, Ramakrishnan S et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation 114(17), 1807–1810 (2006).
  • Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Søndergaard L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur. Heart J. 31(9), 1124–1131 (2010).
  • D’Alto M, Romeo E, Argiento P et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int. J. Cardiol. 155(3), 378–382 (2012).
  • Galiè N, Rubin Lj, Hoeper M et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371(9630), 2093–2100 (2008).
  • Dimopoulos K, Inuzuka R, Goletto S et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 121(1), 20–25 (2010).
  • Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann. Intern. Med. 145(2), 152–153 (2006).
  • Hoeper MM, Barst RJ, Bourge RC et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 127(10), 1128–1138 (2013).
  • Peacock A, Keogh A, Humbert M. Endpoints in pulmonary arterial hypertension: the role of clinical worsening. Curr. Opin. Pulm. Med. 16(Suppl. 1), S1–S9 (2010).
  • Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346(12), 896–903 (2002).
  • Christensen DD, McConnell ME, Book WM, Mahle WT. Initial experience with bosentan therapy in patients with the Eisenmenger syndrome. Am. J. Cardiol. 94(2), 261–263 (2004).
  • Barst RJ, Langleben D, Frost A et al.; STRIDE-1 Study Group. Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 169(4), 441–447 (2004).
  • Gatzoulis MA, Rogers P, Li W et al. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int. J. Cardiol. 98(1), 147–151 (2005).
  • Kotlyar E, Sy R, Keogh AM et al. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease. Cardiol. Young 16(3), 268–274 (2006).
  • Benza RL, Rayburn BK, Tallaj JA et al. Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease. Chest 129(4), 1009–1015 (2006).
  • Sitbon O, Beghetti M, Petit J et al. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. Eur. J. Clin. Invest. 36(Suppl. 3), 25–31 (2006).
  • Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am. Heart J. 151(4), 851.e1–851.e5 (2006).
  • Barst RJ, Langleben D, Badesch D et al.; STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J. Am. Coll. Cardiol. 47(10), 2049–2056 (2006).
  • D’Alto M, Vizza CD, Romeo E et al. Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect. Heart 93(5), 621–625 (2007).
  • Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study. Heart 93(3), 350–354 (2007).
  • Diller GP, Dimopoulos K, Kaya MG et al. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart 93(8), 974–976 (2007).
  • Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int. J. Cardiol. 120(3), 301–305 (2007).
  • Galiè N, Olschewski H, Oudiz RJ et al.; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117(23), 3010–3019 (2008).
  • Galiè N, Brundage BH, Ghofrani HA et al.; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation 119(22), 2894–2903 (2009).
  • Duffels MG, Vis JC, van Loon RL et al. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down’s syndrome. Am. J. Cardiol. 103(9), 1309–1315 (2009).
  • Kermeen FD, Franks C, O’Brien K et al. Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21. Heart. Lung Circ. 19(10), 595–600 (2010).
  • Lu XL, Xiong CM, Shan GL et al. Impact of sildenafil therapy on pulmonary arterial hypertension in adults with congenital heart disease. Cardiovasc. Ther. 28(6), 350–355 (2010).
  • D’Alto M, Romeo E, Argiento P et al. Therapy for pulmonary arterial hypertension due to congenital heart disease and Down’s syndrome. Int. J. Cardiol. 164(3), 323–326 (2013).
  • Zeng WJ, Lu XL, Xiong CM et al.; Sildenafil Therapy on Pulmonary Arterial Hypertension Associated With Different Types of Congenital Heart Disease Study Group. The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease. Clin. Cardiol. 34(8), 513–518 (2011).
  • Monfredi O, Griffiths L, Clarke B, Mahadevan VS. Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease. Am. J. Cardiol. 108(10), 1483–1488 (2011).
  • Dong MF, Ma ZS, Ma SJ et al. Effect of prostaglandin E1 on pulmonary arterial hypertension following corrective surgery for congenital heart disease. J. Cardiovasc. Pharmacol. Ther. 17(3), 303–307 (2012).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.